HFpEF, Eli Lilly and tirzepatide

Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients
Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year median follow-up. Patients on tirzepatide showed a 56% reduction in heart failure hospitalizations and significant improvements in ...
AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT
Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly
SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions remain.
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Renal & Urology News32m
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
(HealthDay News) — For patients with obesity and prediabetes, 3 years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according ...
FiercePharma5d
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
GlobalData on MSN4d
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
Business Insider15h
Eli Lilly’s Promising Prospects and New Product Pipeline Drive Buy Rating
Management at Eli Lilly has expressed strong confidence in the growing demand for their obesity franchise and a robust pipeline of new products. The company is anticipating significant benefits ...
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...
Verywell Health on MSN4d
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...